DataMeds AI, Inc.
No SEC Form 4 filings for $MEDS in the last 30 days.
See all $MEDS insider activity →DataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 DataMeds AI Reports Second Quarter 2026 Financials and Provides Business Update ■ Health Lives Here app launch with NFL Alumni Health expected in September 2026 ■ Revenues grew 14% reaching $1.779M in Q2/26, beating management projections
DataMeds AI, Inc. (NASDAQ:MEDS) said its board set Sept. 9, 2026 as the payment date for a previously announced distribution of Dream Bowl Meme Coin I tokens to record holders as of Aug. 7, 2026. Holders will receive 50 tokens per share. The company plans to distribute about 153,631,650 tokens and list them on Biconomy in Q3 2026.
DataMEDS AI, Inc. (NASDAQ:MEDS) said its board set Sept. 9, 2026 as the payment date for a previously announced distribution of Dream Bowl Meme Coin I tokens to record holders as of Aug. 7, 2026. Holders get 50 tokens per share. About 3,072,633 shares outstanding; ~153,631,650 tokens planned. Tokens may be listed on Biconomy in Q3 2026.
Over the past 7 days, alphai's AI scored 5 news stories mentioning MEDS (DataMeds AI, Inc.). Coverage has been balanced: 1 bullish, 3 neutral, and 1 bearish.
Recent MEDS coverage spans corporate actions, financial news and earnings.
Near-term trading is likely driven by financing, restructuring, and the credibility/timing of the September 2026 consumer app and Datavault-related consolidation.
This is a corporate action tied to a crypto token distribution, with an opt-in wallet requirement and explicit risk that tokens may have no value.
This is a corporate action tied to a token distribution, with potential near-term sentiment and liquidity effects around the token claim process and planned exchange listing.
The filing delay increases near-term reporting uncertainty and can pressure liquidity and sentiment until the extended 10-Q is actually submitted.
Near-term upside case is incremental commercialization of Corexa Pharmacy via the Health Lives Here app and GLP-1-focused product availability; downside is execution and regulatory/partner dependency risk.
alphai scores every news story that mentions MEDS with an AI model for sentiment and relevance, and aggregates insider trades from DataMeds AI, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
DataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 DataMeds AI Reports Second Quarter 2026 Financials and Provides Business Update ■ Health Lives Here app launch with NFL Alumni Health expected in September 2026 ■ Revenues grew 14% reaching $1.779M in Q2/26, beating management projections
6 min readDataMeds AI, Inc. (NASDAQ:MEDS) said its board set Sept. 9, 2026 as the payment date for a previously announced distribution of Dream Bowl Meme Coin I tokens to record holders as of Aug. 7, 2026. Holders will receive 50 tokens per share. The company plans to distribute about 153,631,650 tokens and list them on Biconomy in Q3 2026.
4 min readDataMEDS AI, Inc. (NASDAQ:MEDS) said its board set Sept. 9, 2026 as the payment date for a previously announced distribution of Dream Bowl Meme Coin I tokens to record holders as of Aug. 7, 2026. Holders get 50 tokens per share. About 3,072,633 shares outstanding; ~153,631,650 tokens planned. Tokens may be listed on Biconomy in Q3 2026.
3 min readDataMEDS AI, Inc. (MEDS) filed a Notification of Late Filing for its Q2 2026 Form 10-Q, saying it will miss the original Aug. 14, 2026 due date for the quarter ended June 30, 2026. The company cited needing additional time to complete financial statements and disclosures, and expects to file within the five-day Rule 12b-25 extension.
2 min readDataMeds AI (NASDAQ:MEDS) said its Corexa Health pharmacy division, Corexa Pharmacy, has completed the CorexaRx.com store integration into the Health Lives Here app and added access to oral GLP-1 drugs and injectable GLP-1s. It reported July 2026 revenue above $600,000, stabilizing a run rate above $7 million annually, and said Forzet, Galectovid, and Tollovid are now available.
6 min readDataMeds AI, Inc. (NASDAQ:MEDS) reiterated that Aug. 7, 2026 is the record date for a 50:1 Dream Bowl Meme Coin token to DataMeds common shares dividend ratio, according to the company. The token is listed on Biconomy, and the company said it intends to pursue fail-to-deliver notices aggressively.
2 min readDataMeds AI (MEDS) said it signed an amended letter of intent to gain control of Tollo Health, license QOLPOM-related IP from EOS Technology Holdings and Scilex, and expand its Datavault AI Health license. Consideration is in common stock only. EOS, Scilex, Datavault AI and HealthBridge Advisors are expected to hold about 84.6% post-closing, Fortitude about 5%, subject to adjustments. Closing depends on definitive deals, financing, approvals and Nasdaq.
1 min readDataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 AMENDED AND RESTATED LETTER OF INTENT July 29, 2026 This Amended and Restated Letter of Intent (this “ LOI ”) sets forth our current proposal with regard to the proposed combination (the “ Transaction ”) of DataMEDS AI, Inc., a reporting
7 min readDataMeds AI (NASDAQ:MEDS) said its wholly owned Corexa Pharmacy has started DTC distribution of Tollo Health’s Tollovid, a 3CL protease inhibitor dietary supplement, and Galactovid, a medical food for galectin-1/3 associated viral infections. DataMeds also disclosed a non-binding letter of intent to acquire a controlling interest in Tollo Health.
4 min readDataMeds AI (NASDAQ:MEDS) said its wholly owned Corexa Pharmacy has started DTC distribution via CorexaRx of Tollo Health’s Tollovid (a 3CL protease inhibitor dietary supplement) and Galactovid (a medical food for galectin-1/3 associated viral infections). DataMeds AI also disclosed a non-binding LOI to acquire a controlling interest in Tollo Health, subject to definitive agreements and closing conditions.
4 min read
